Clinical trial · no report yet · Phase 2
NEOLA
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
- NCT06194448 ↗
- Active, not recruiting
- AstraZeneca
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 5 | |
| Podcasts | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Lung Cancer
- Interventions
- Osimertinib; Cisplatin or Carboplatin; Pemetrexed or Paclitaxel; Radiation
- Arms
- Open-Label Osimertinib Induction Treatment · Experimental
- Enrollment
- 76
- Primary outcomes
- PFS (Progression-Free Survival)
- Sponsor
- AstraZeneca
- Start
- Apr 21, 2024
- Primary completion
- Jul 7, 2026
- Results posted
- No
- Registry record
- NCT06194448 · updated Aug 19, 2026
Publications
linked from the registry- Aredo JV, Peled N, Arriola E, Wakelee H, Ahn MJ, Kwint MH, Taylor R, van der Gronde T, Nasirova F, Chen M. Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol. Future Oncol. 2025 Dec;21(29):3731-3737. doi: 10.1080/14796694.2025.2587569. Epub 2025 Nov 14. PubMed 41236484